// App-Quantinova.ai

: Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results

Researchers

Presenter

  • Patrice Nasnas

Principal Investigators

  • Nicholas Short

  • Koji Sasaki

  • Farhad Ravandi

  • Nitin Jain

  • Naval Daver

  • Naveen Pemmaraju

  • Musa Yilmaz

  • Tapan M. Kadia

  • Rebecca Garris

  • Guillermo Garcia-Manero

  • Courtney D. DiNardo

  • Marina Konopleva

  • William G. Wierda

  • Monica Kwari

  • Christopher Loiselle

  • Anna Milton

  • Juan Rivera

  • Glenda Banks

  • Hagop Kantarjian

Medical Centers

  • MD Anderson Cancer Center, Houston, TX

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Leukemia, MD Anderson Cancer Center, Houston, TX

  • The University of Texas M.D. Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Creatinine

Drug/Treatment

  • Methotrexate

  • Vincristine

  • Cytarabine liposomal

  • Prednisone

  • Ponatinib

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Single Arm

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved